» Articles » PMID: 21471963

Transporter-mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions

Overview
Publisher Wiley
Specialty Pharmacology
Date 2011 Apr 8
PMID 21471963
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Transporter proteins mediate the cellular uptake and efflux of a broad variety of endogenous compounds, drugs, and their metabolites. Their systemic plasma concentrations are determined, in particular, by drug transporters expressed in the small intestine, liver, and kidney. In addition, drug transporters expressed in peripheral tissues (e.g., skeletal muscle) are likely to influence organ-specific drug concentrations and side effects. This review summarizes current findings regarding the association between adverse drug reactions in humans and modification of the functions of certain transporters caused by genetic factors or simultaneously administered inhibitors. We focus on adverse drug reactions occurring in humans due to transport in the small intestine, liver, kidneys, and blood-brain barrier.

Citing Articles

Assessment of P-glycoprotein function using canine intestinal organoid-derived epithelial interfaces.

Nagao I, Nakazawa M, Tachibana Y, Kawasaki M, Ambrosini Y Xenobiotica. 2024; 54(6):342-349.

PMID: 38819399 PMC: 11325560. DOI: 10.1080/00498254.2024.2358395.


Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat.

Chang C, Peng W, Lee W, Yang L, Lin T, Yang M Commun Med (Lond). 2023; 3(1):150.

PMID: 37857815 PMC: 10587300. DOI: 10.1038/s43856-023-00383-w.


Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development.

Hau R, Wright S, Cherrington N Clin Pharmacol Ther. 2023; 114(4):780-794.

PMID: 37404197 PMC: 11347013. DOI: 10.1002/cpt.2984.


Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.

Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y Cancer Res Commun. 2022; 2(11):1334-1343.

PMID: 36506732 PMC: 9730833. DOI: 10.1158/2767-9764.crc-22-0172.


A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.

Li Y, Jin Y, Taheri H, Schmidt K, Gibson A, Buck S Pharmaceutics. 2022; 14(9).

PMID: 36145680 PMC: 9502272. DOI: 10.3390/pharmaceutics14091933.